To identify the molecular trigger behind the rare clotting disorder linked to adenovirus-based COVID-19 vaccines.
Key Findings:
The immune response mistakenly targets platelet factor 4 (PF4), a normal blood protein involved in clotting.
Adenoviral core protein VII (pVII) was identified as the likely inciting antigen for the immune response.
Nearly all patients with vaccine-induced immune thrombocytopenia and thrombosis (VITT) shared a specific immunoglobulin light-chain variant.
Reversing a specific somatic mutation (K31E) in recombinant antibodies reduced PF4 binding and clot-promoting activity.
Interpretation:
The findings elucidate how a normal immune response can, in rare cases, lead to harmful clotting disorders, suggesting that the adenoviral vector protein may be a key factor.
Limitations:
Further studies are needed to evaluate the safety of modified adenoviral vaccine platforms.
The study focused on a limited patient population, which may not represent all cases.
Conclusion:
Modifying or removing the adenoviral protein pVII could help avoid rare clotting reactions in future vaccines while maintaining their efficacy.
